FDA warns Buy Keta Online that its website sells unapproved and misbranded ketamine drugs to U.S. consumers.
What happened
FDA reviewed www.buyketaonline.com on March 2, 2026 and found it offering ketamine liquid, ketamine capsules for depression, and esketamine nasal spray to U.S. consumers. FDA says these are unapproved new drugs and misbranded drugs, and that the capsules and nasal spray did not meet the legal conditions for compounded drugs to avoid FDA approval. FDA also says the site offered prescription drugs without requiring a prescription.
What FDA found
The website offered ketamine liquid for human use without an FDA-approved drug application.
Sections 505(a) and 301(d), FD&C Act (21 U.S.C. 355(a), 331(d))The website offered compounded ketamine capsules for depression and esketamine nasal spray that did not meet the legal conditions for compounded drugs to be exempt from FDA approval.
Sections 503A, 503B, 505(a), and 301(d), FD&C Act (21 U.S.C. 353a, 353b, 355(a), 331(d))The prescription drug labeling did not include adequate directions for use, so FDA calls the products misbranded.
Section 502(f)(1), FD&C Act (21 U.S.C. 352(f)(1))The website offered prescription drugs without requiring a prescription, which FDA says misbrands them.
Sections 503(b)(1) and 301(k), FD&C Act (21 U.S.C. 353(b)(1), 331(k))
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs to U.S. consumers and to send a written response within 15 business days describing corrections, prevention steps, and supporting documents.
Who should pay attention
- online pharmacies and telehealth sellers
- clinics and practitioners considering ketamine products
- consumers and companies that buy or promote unapproved ketamine
This is a summary. Read the original letter on fda.gov.